Deutsche Bank AG restated their buy rating on shares of Stryker Co. (NYSE:SYK) in a research report released on Saturday, April 29th. They currently have a $148.00 price target on the medical technology company’s stock, up from their previous price target of $135.00.
Other research analysts also recently issued reports about the stock. Oppenheimer Holdings Inc. set a $135.00 price objective on shares of Stryker and gave the company a hold rating in a research note on Saturday, April 8th. BMO Capital Markets reiterated a hold rating and set a $125.00 price objective on shares of Stryker in a research note on Tuesday, April 11th. Jefferies Group LLC reiterated a hold rating and set a $132.00 price objective on shares of Stryker in a research note on Thursday, April 13th. Piper Jaffray Companies reiterated an overweight rating and set a $148.00 price objective on shares of Stryker in a research note on Monday, April 17th. Finally, Barclays PLC reiterated a sell rating and set a $133.00 price objective on shares of Stryker in a research note on Thursday, April 27th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $134.81.
Shares of Stryker (NYSE:SYK) traded up 0.96% during trading on Friday, reaching $136.13. 599,257 shares of the company were exchanged. The stock has a market capitalization of $50.88 billion, a P/E ratio of 30.59 and a beta of 0.80. Stryker has a 1-year low of $106.48 and a 1-year high of $136.79. The firm has a 50-day moving average price of $133.43 and a 200-day moving average price of $124.63.
Stryker (NYSE:SYK) last announced its earnings results on Tuesday, April 25th. The medical technology company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.05. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.90 billion. Stryker had a net margin of 14.54% and a return on equity of 23.86%. The business’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.24 earnings per share. Equities research analysts predict that Stryker will post $6.43 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.chaffeybreeze.com/2017/05/19/deutsche-bank-ag-reaffirms-buy-rating-for-stryker-co-syk-updated-updated.html.
The company also recently announced a quarterly dividend, which will be paid on Monday, July 31st. Shareholders of record on Friday, June 30th will be issued a $0.425 dividend. This represents a $1.70 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Wednesday, June 28th. Stryker’s payout ratio is 39.08%.
In related news, insider Timothy J. Scannell sold 13,322 shares of the firm’s stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $135.89, for a total transaction of $1,810,326.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.80% of the company’s stock.
Several hedge funds have recently bought and sold shares of SYK. Whitnell & Co. boosted its stake in Stryker by 73.6% in the third quarter. Whitnell & Co. now owns 3,775 shares of the medical technology company’s stock valued at $439,000 after buying an additional 1,600 shares in the last quarter. Stack Financial Management Inc boosted its stake in Stryker by 0.8% in the third quarter. Stack Financial Management Inc now owns 229,427 shares of the medical technology company’s stock valued at $26,708,000 after buying an additional 1,869 shares in the last quarter. Nwam LLC bought a new stake in Stryker during the third quarter valued at approximately $223,000. Nelson Roberts Investment Advisors LLC boosted its stake in Stryker by 24,873.3% in the third quarter. Nelson Roberts Investment Advisors LLC now owns 56,190 shares of the medical technology company’s stock valued at $6,541,000 after buying an additional 55,965 shares in the last quarter. Finally, GHP Investment Advisors Inc. boosted its stake in Stryker by 1.7% in the third quarter. GHP Investment Advisors Inc. now owns 25,120 shares of the medical technology company’s stock valued at $2,924,000 after buying an additional 424 shares in the last quarter. Institutional investors and hedge funds own 75.29% of the company’s stock.
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Co. and related companies with MarketBeat.com's FREE daily email newsletter.